HS
CCCC icon

HighVista Strategies’s C4 Therapeutics CCCC Stock Holding History

HighVista Strategies’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-34,760
Closed -$843K – 111
2022
Q1 		$843K Buy
34,760
+3,267
+10% +$79.3K 0.54% 53
2021
Q4 		$1.01M Buy
31,493
+2,152
+7% +$85.1K 0.81% 46
2021
Q3 		$1.31M Buy
29,341
+7,612
+35% +$326K 0.87% 28
2021
Q2 		$822K Buy
21,729
+4,142
+24% +$148K 0.58% 36
2021
Q1 		$651K Buy
+17,587
New +$700K 0.48% 49

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HighVista Strategies's CCCC Position: Q2 2022 in Review

HighVista Strategies sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 34,760 shares — an estimated $843K sold.

HighVista Strategies first reported a position in CCCC in Q1 2021 and held it in 5 quarters. The position peaked at $1.31M in Q3 2021. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

  • HighVista Strategies reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • HighVista Strategies sold 34,760 C4 Therapeutics shares in Q2 2022, an estimated $843K.
  • HighVista Strategies first reported a position in C4 Therapeutics in Q1 2021 and held it in 5 quarters.
  • HighVista Strategies's C4 Therapeutics position peaked at $1.31M in Q3 2021.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on HighVista Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.